PLoS By Category | Recent PLoS Articles

Biochemistry - Computer Science - Immunology - Mathematics - Nephrology - Oncology - Pathology - Pediatrics and Child Health

Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients
Published: Friday, December 16, 2011
Author: Jana Schmitt et al.

by Jana Schmitt, Andreas Keller, Nasenien Nourkami-Tutdibi, Sabrina Heisel, Nunja Habel, Petra Leidinger, Nicole Ludwig, Manfred Gessler, Norbert Graf, Frank Berthold, Hans-Peter Lenhof, Eckart Meese

Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.